Page 2 of 18: studies 21 to 40 of 355, newest first. Back to the ketamine overview
JAMA Psychiatry December 1, 2023 Sanjay J. Mathew, Manish K. Jha, Amit Anand 8 citations
This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD).
Pharmacology, Biochemistry, and Behavior December 1, 2023 Guilin Liu, Li Ma, Youge Qu et al. 16 citations
Anesthetic ketamine and classical psychedelics that act as 5-hydroxytryptamine-2A receptor (5-HT2AR) agonists demonstrated rapid and sustained antidepressant actions in patients with treatment-resistant depression. The new antidepressant arketamine is reported to cause long-lasting prophylactic effects in lipopolysaccharide (LPS)-treated mice and mice exposed to chronic restrain stress (CRS)....
Drug and Alcohol Dependence December 1, 2023 Caryssa R Drinkuth, Michael J Lehane, Gregory C Sartor 9 citations
Despite the thousands of lives lost during the ongoing opioid crisis, a scarcity of new and effective clinical treatments for opioid use disorder (OUD) remains. To address this unmet need, some researchers have turned to dissociative and psychedelic drugs to treat multiple psychiatric conditions. In particular, low doses of ketamine have been shown to attenuate opioid withdrawal and drug use in...
medRxiv Preprint Server December 1, 2023 Brandon Taraku, Joana R Loureiro, Ashish K Sahib et al. 1 citation preprint
Dysfunctional reward processing in major depressive disorder (MDD) involves functional circuitry of the habenula (Hb) and nucleus accumbens (NAc). Ketamine elicits rapid antidepressant and alleviates anhedonia in MDD. To clarify how ketamine perturbs reward circuitry in MDD, we examined how serial ketamine infusions (SKI) modulate static and dynamic functional connectivity (FC) in Hb and NAc...
Pharmacological Reports December 1, 2023 Magdalena Kolasa, Agata Faron-Górecka 18 citations
Treatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to achieve satisfactory treatment results. Although there are various definitions and grading models for TRD, common criteria for assessing TRD have still not been established. However, a common feature of any TRD model is the lack of response to at least...
Pharmacological Reports December 1, 2023 Adam Wojtas 10 citations
Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting the lives of millions of patients. While crucial in the history of drug development, recent studies undermine the effectiveness of currently used antidepressant drugs in comparison to placebo, emphasizing the long time it takes to initiate the...
Proceedings of the National Academy of Sciences November 27, 2023 John H. Krystal, Alfred P. Kaye, Sarah J. Jefferson et al. 66 citations
Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and protection against relapse distinguish it from prior antidepressants. Its discovery emerged from a reconceptualization of the neurobiology of depression and, in turn, insights from the elaboration of its mechanisms of action...
Frontiers in Psychiatry November 23, 2023 Florian Buchmayer, Siegfried Kasper 19 citations
Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact on many humans lives worldwide and more than a third of treated people are not responding after several treatment attempts. Additional...
European Psychiatry November 17, 2023 Émeline Gaudré-Wattinne, Lila Mekaoui, Maud Rothärmel et al. 1 citation
Introduction Esketamine nasal spray has been developed for patients with treatment resistant depression. Objectives A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods On 02/08/2019 the French National Agency for Medicines and Health Product Safety granted an early access program for Esketamine nasal spray framed by a...
European Psychiatry November 17, 2023 N. Veluri, Zeeshan Mansuri 1 citation
Introduction Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span of 24-hours. Recently, the FDA approved esketamine, an enantiomer of ketamine for TRD. Objectives To determine the effectiveness of ketamine and...
Australasian Psychiatry November 14, 2023 Judith D. Hope, David L Copolov, John Tiller et al.
Objective To review the usefulness of esketamine for treatment-resistant depression. Method Pivotal trials of intranasal esketamine in treatment-resistant depression were synthesized as a narrative review. Results Esketamine is postulated to act through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, but opioidergic effects may also be involved. Unlike intravenous ketamine,...
Mental Health Weekly November 13, 2023 Valerie A. Canady
Observing that ketamine infusion therapy is increasingly being used for such mental health conditions as major depressive disorder, bipolar disorder, treatment‐resistant depression, and post‐traumatic stress disorder, two national nursing associations have released a joint statement indicating that patients with psychiatric disorders may benefit from the use of ketamine infusion therapy.
Pharmacology, Biochemistry, and Behavior November 8, 2023 Aida A.C. Brandão, D. L. S. Deus, L. A. Duarte-Filho et al.
Major depressive disorder (MDD) is a debilitating illness that affects millions of people worldwide. Currently available antidepressants often take weeks to months to reach their full effect, which leads to an increased risk of suicidal behavior in patients with MMD. Intranasally, esketamine has emerged as an alternative to current antidepressants because of its rapid onset and long-lasting...
Journal of Affective Disorders November 8, 2023 Itsuki Terao, Takahiro Tsuge, Kaori Endo et al. 32 citations
BACKGROUND Intravenous racemic ketamine is a promising treatment for treatment-resistant depression. However, its clinical utility compared with intranasal esketamine and the other well-studied conventional pharmacological interventions (i.e., aripiprazole and lithium) as augmentative treatments for treatment-resistant unipolar depression in adults remains unclear. Therefore, we aimed to...
bioRxiv Preprint Server November 7, 2023 Kelly E. Dunham, Kani H. Khaled, Leah Weizman et al. preprint
Recently, the FDA approved microdosing ketamine for treatment resistant depression. Traditional antidepressants, like serotonin selective reuptake inhibitors (SSRIs), block serotonin reuptake, but it is not clear if ketamine blocks serotonin reuptake. Here, we tested the effects of feeding ketamine and SSRIs to Drosophila melanogaster larvae, which has a similar serotonin system to mammals, and...
Legal medicine (Tokyo, Japan) November 2023 Yanxia Peng, Yihang Wang, Linlin Liu et al.
Combined methamphetamine (MA) and ketamine (KET) abuse is a serious issue. At present, however, few studies have explored the mechanism underlying their combined addiction. We established a rat conditioned place preference (CPP) model. We investigated the role of dopamine (DA), 5-hydroxytryptamine (5-HT), monoamine oxidase (MAO), glutamate receptor 1 (GluR1), and glutamate receptor 2 (GluR2) in...
Quality of Life Research November 2023 Carol Jamieson, Carla M. Canuso, Dawn F. Ionescu et al.
To assess the effect of esketamine nasal spray on patient-reported outcomes (PROs) in patients with major depressive disorder having active suicidal ideation with intent (MDSI). Patient-level data from two phase 3 studies (ASPIRE I; ASPIRE II) of esketamine + standard of care (SOC) in patients (aged 18-64 years) with MDSI, were pooled. PROs were evaluated from baseline through end of the...
Journal of the Academy of Consultation-Liaison Psychiatry November 1, 2023 Charalambia Louka, Stephanie Chiao
BACKGROUND Ketamine is an anesthetic and analgesic known for its psychotomimetic properties, such as dissociation and altered perception. Acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) are characterized by unwanted memories, intrusive thoughts, and dissociative flashbacks following an acute traumatic event. It is unknown how analgesic ketamine affects the symptomatology of...
Journal of Trauma Nursing November 1, 2023 Caitlyn B. Coffelt, Kyle Gibson, Jason VanLandingham
BACKGROUND: This case report describes the use of ketamine as a rapid, effective treatment of depression in a 68-year-old female patient with no significant medical history of psychiatric disorders. Patients who experience intentional or unintentional traumas are at an increased risk for developing depression or posttraumatic stress disorder, and emerging evidence has supported the use of...
National Science Review November 1, 2023 Xu Liu, Zhixian Cheng, He Lin et al.
Oculomotor behavior has been shown to be correlated with mental disorders in clinics, making it promising for disease diagnosis. Here we developed a thorough oculomotor test toolkit, involving saccade, smooth pursuit, and fixation, allowing the examination of multiple oculomotor parameters in monkey models induced by psychoactive drugs. Eye movements were recorded after daily injections of...